committee of 18, and all recommendations have 100% approval from the steering committee and the authors of each chapter. This removes as much bias as possible. The ADA/EASD consensus group consists of seven members and emphasises 'our collective knowledge and clinical experience, which takes into account benefits, risks and costs…'. Neither publication specifically provides a cost analysis. The CDA believes cost analyses are inconsistent in methodology and lack assessments on hypoglycaemia and quality of life, and therefore omitted them.
The algorithms differ in the choice of medications to prescribe when metformin fails to control hyperglycaemia. In contrast to the consensus statement, which has a two-tier system, the CDA guidelines give equal weight to the following classes of medications that are available in Canada (listed alphabetically): alpha-glucosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, insulin, insulin secretagogues, thiazoledinediones and weight-loss agents.
It is of concern that the consensus paper has a two-tier approach with only basal insulin and sulfonylureas as the preferred choices after metformin. Our committee believes that patients and practitioners deserve more choice. Nathan et al. state that they take costs into account, but they do not factor self-monitoring of blood glucose into their algorithm. In addition, the consensus statement does not recommend glibenclamide (known as glyburide in the USA and Canada), which is probably the least expensive sulfonylurea, and it further states that sulfonylureas should be discontinued when insulin is used. Therefore, when basal insulin with an intermediate-acting insulin is used it is very likely that more than one injection will be required.
With regard to thiazoledinediones, we have not found that there is evidence to exclude rosiglitazone, based on recent evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) and VA Diabetes (VADT) trials [4] [5] [6] , which do not show an increased risk of myocardial infarction. Moreover, these trials were specifically designed to address this question, in contrast to the studies quoted in the consensus statement.
In summary, both approaches have merits but differ in important ways. The CDA evidence-based approach gives more flexibility, while the consensus approach is more directive and more opinion-based.
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